Dumont & Blake Investment Advisors LLC Invests $1.18 Million in IQVIA Holdings Inc. $IQV

Dumont & Blake Investment Advisors LLC bought a new stake in IQVIA Holdings Inc. (NYSE:IQV) during the first quarter, HoldingsChannel.com reports. The fund bought 6,890 shares of the medical research company’s stock, valued at approximately $1,175,000.

Several other institutional investors have also recently bought and sold shares of the company. Ameliora Wealth Management Ltd. bought a new position in shares of IQVIA during the 4th quarter worth approximately $25,000. International Assets Investment Management LLC acquired a new stake in shares of IQVIA in the fourth quarter valued at approximately $27,000. Gilpin Wealth Management LLC bought a new stake in shares of IQVIA in the fourth quarter worth $27,000. CrossGen Wealth LLC acquired a new position in IQVIA during the fourth quarter worth $28,000. Finally, Activest Wealth Management grew its position in IQVIA by 590.0% in the fourth quarter. Activest Wealth Management now owns 138 shares of the medical research company’s stock valued at $31,000 after purchasing an additional 118 shares in the last quarter. Institutional investors own 89.62% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on IQV. HSBC restated a “buy” rating and set a $240.00 price objective on shares of IQVIA in a research note on Monday. TD Cowen upgraded IQVIA from a “hold” rating to a “buy” rating and upped their target price for the stock from $174.00 to $213.00 in a report on Monday, March 9th. Evercore restated an “outperform” rating and issued a $185.00 price target on shares of IQVIA in a research note on Wednesday, April 8th. Weiss Ratings lowered IQVIA from a “hold (c)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. Finally, Robert W. Baird upped their price objective on IQVIA from $230.00 to $249.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 1st. Fourteen analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, IQVIA currently has an average rating of “Moderate Buy” and a consensus target price of $223.88.

IQVIA Stock Performance

IQV opened at $206.07 on Tuesday. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 2.20. IQVIA Holdings Inc. has a 12-month low of $154.50 and a 12-month high of $247.04. The business has a 50 day moving average of $177.86 and a 200-day moving average of $188.95. The stock has a market cap of $34.39 billion, a price-to-earnings ratio of 25.54, a PEG ratio of 1.78 and a beta of 1.20.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 earnings per share for the quarter, beating analysts’ consensus estimates of $2.83 by $0.07. IQVIA had a return on equity of 30.50% and a net margin of 8.33%.The business had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. During the same quarter in the prior year, the business earned $2.70 EPS. The firm’s revenue for the quarter was up 8.4% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. On average, equities research analysts expect that IQVIA Holdings Inc. will post 11.6 earnings per share for the current year.

IQVIA announced that its board has initiated a share repurchase program on Thursday, May 7th that authorizes the company to buyback $2.00 billion in shares. This buyback authorization authorizes the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board believes its stock is undervalued.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.